Table 2.
Base case results for an analysis of ART monitoring in Mozambique.
| Performance Characteristics | Projected Clinical and Economic Outcomes | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | Positive Predictive Value (%) | Negative Predictive Value (%) | Years on Failed ART | Undiscounted Life Years | Discounted Life Years* | Discounted Costs* (2014 US$) | ICER ($/YLS) | |
| Rural Setting | |||||||||
| CLIN | 1.4 | 99.7 | 70.7 | 69.5 | 4.4 | 17.1 | 11.5 | 2,360 | - |
| POC-CD412 | 34.6 | 99.3 | 93.8 | 83.5 | 3.8 | 19.9 | 12.8 | 3,000 | 490 |
|
| |||||||||
| Urban Setting | |||||||||
| LAB-CD46 | 23.7 | 99.5 | 92.2 | 83.9 | 3.9 | 19.8 | 12.7 | 3,120 | - |
| VL12 | 89.0 | 100.0 | 100.0 | 98.4 | 2.9 | 20.4 | 13.0 | 3,250 | 440 |
| POC-CD46 | 24.9 | 99.0 | 85.8 | 84.3 | 4.1 | 19.8 | 12.8 | 3,380 | DOMINATED |
CLIN, clinical ART monitoring strategy; POC-CD4, point-of-care CD4 ART monitoring strategy; LAB-CD4, laboratory CD4 ART monitoring strategy; VL, HIV RNA ART monitoring strategy; ICER, incremental cost-effectiveness ratio; YLS, year of life saved; DOMINATED indicates that a strategy is more expensive and confers less clinical benefit than an alternative strategy. Subscripts denote number of months between tests in a given strategy.
*
Discounted at 3%